Comparative effectiveness of the BNT162b2 and ChAdOx1 vaccines against Covid-19 in people over 50

Junqing Xie; Shuo Feng; Xintong Li; Ester Gea-Mallorquí; Albert Prats-Uribe; Dani Prieto-Alhambra

doi:10.1038/s41467-022-29159-x

Nature Communications (Mar 2022)

Comparative effectiveness of the BNT162b2 and ChAdOx1 vaccines against Covid-19 in people over 50

Junqing Xie,
Shuo Feng,
Xintong Li,
Ester Gea-Mallorquí,
Albert Prats-Uribe,
Dani Prieto-Alhambra

Affiliations

Junqing Xie: Centre for Statistics in Medicine, NDORMS, University of Oxford
Shuo Feng: Oxford Vaccine Group, Department of Paediatrics, University of Oxford
Xintong Li: Centre for Statistics in Medicine, NDORMS, University of Oxford
Ester Gea-Mallorquí: Nuffield Department of Clinical Medicine, University of Oxford
Albert Prats-Uribe: Centre for Statistics in Medicine, NDORMS, University of Oxford
Dani Prieto-Alhambra: Centre for Statistics in Medicine, NDORMS, University of Oxford

DOI: https://doi.org/10.1038/s41467-022-29159-x
Journal volume & issue: Vol. 13, no. 1
pp. 1 – 8

Abstract

Read online

Several vaccines have been approved for Covid-19 and effectiveness data could guide public health decisions on vaccine usage. Here, the authors compare effectiveness of BNT162b2 and ChAdOx1 vaccines in people over 50 in the UK and find that BNT162b2 confers lower risk of infection and hospitalization.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal